Search research articles
Contact Us
Filters
Showing results (561-570 of 643) with videos related to
Page
of 65
Sort By:
JAMA Network Open
|
October 14, 2022
Association of Prediagnosis Obesity and Postdiagnosis Aspirin With Survival From Stage IV Colorectal Cancer
Jennifer S Davis, Janelle C Chavez, Melissa Kok, et al.
JCO Precision Oncology
|
December 1, 2023
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With <i>ATM</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Nitin Rohatgi, Michael Rothe, Pam K Mangat, et al.
Nature
|
March 25, 2021
Breast tumours maintain a reservoir of subclonal diversity during expansion
Darlan C Minussi, Michael D Nicholson, Hanghui Ye, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 20, 2023
National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)
Funda Meric-Bernstam, James M Ford, Peter J O'Dwyer, et al.
Nature Medicine
|
June 5, 2023
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results
Timothy A Yap, Elisa Fontana, Elizabeth K Lee, et al.
NPJ Precision Oncology
|
May 30, 2026
Cyclin E1 overexpression identifies a therapeutically relevant poor prognostic patient subgroup in high-grade serous ovarian cancer
Doris Kim, Heekyung Chung, Mona Abed, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 27, 2021
A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies
Aparna Hegde, Priyamvada Jayaprakash, Coline A Couillault, et al.
JCO Precision Oncology
|
December 14, 2023
Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With <i>BRAF</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study
Funda Meric-Bernstam, Michael Rothe, Pam K Mangat, et al.
Cancer
|
November 2, 2018
Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies
Minny Bhatty, Shumei Kato, Sarina A Piha-Paul, et al.
Journal of the National Cancer Institute
|
December 10, 2024
Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial
Yara Abdou, William E Barlow, Julie R Gralow, et al.
Page
of 65
Search research articles
Search
Showing results (561-570 of 643) with videos related to
Sort By:
Page
of 65
JAMA Network Open
|
October 14, 2022
Association of Prediagnosis Obesity and Postdiagnosis Aspirin With Survival From Stage IV Colorectal Cancer
Jennifer S Davis, Janelle C Chavez, Melissa Kok, et al.
JCO Precision Oncology
|
December 1, 2023
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With <i>ATM</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Nitin Rohatgi, Michael Rothe, Pam K Mangat, et al.
Nature
|
March 25, 2021
Breast tumours maintain a reservoir of subclonal diversity during expansion
Darlan C Minussi, Michael D Nicholson, Hanghui Ye, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 20, 2023
National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)
Funda Meric-Bernstam, James M Ford, Peter J O'Dwyer, et al.
Nature Medicine
|
June 5, 2023
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results
Timothy A Yap, Elisa Fontana, Elizabeth K Lee, et al.
NPJ Precision Oncology
|
May 30, 2026
Cyclin E1 overexpression identifies a therapeutically relevant poor prognostic patient subgroup in high-grade serous ovarian cancer
Doris Kim, Heekyung Chung, Mona Abed, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 27, 2021
A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies
Aparna Hegde, Priyamvada Jayaprakash, Coline A Couillault, et al.
JCO Precision Oncology
|
December 14, 2023
Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With <i>BRAF</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study
Funda Meric-Bernstam, Michael Rothe, Pam K Mangat, et al.
Cancer
|
November 2, 2018
Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies
Minny Bhatty, Shumei Kato, Sarina A Piha-Paul, et al.
Journal of the National Cancer Institute
|
December 10, 2024
Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial
Yara Abdou, William E Barlow, Julie R Gralow, et al.
Page
of 65